Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- befree-2016 importedOn "2016-02-19" NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_assertion wasGeneratedBy ECO_0000203 NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_assertion wasDerivedFrom befree-2016 NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_assertion SIO_000772 21908430 NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_assertion evidence source_evidence_literature NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.